Ratg denied as duplicate or overlapping therapy by Humana?

Humana Medicare Advantage plans must follow CMS coverage guidelines, and services must be provided according to Medicare coverage guidelines established by the Centers for Medicare & Medicaid Services (CMS), under which all medical care, services, supplies and equipment must be medically necessary . Under CMS NCD 260.7, the FDA has approved lymphocyte immune globulin, anti-thymocyte globulin (equine) for the management of allograft rejection episodes in renal transplantation, it is covered under Medicare when used for this purpose, and other forms of lymphocyte globulin preparation that the FDA approves for this indication may be covered . The FDA-labeled indication for rabbit ATG is that Thymoglobulin (anti-thymocyte globulin, rabbit) is indicated for the prophylaxis and treatment of acute rejection in adult and pediatric patients receiving a kidney transplant in conjunction with concomitant immunosuppression , with the approved regimen being 1.5 mg/kg of body weight administered daily for 4 to 7 days . Per FDA labeling, Thymoglobulin is contraindicated in patients with a history of allergy or anaphylaxis to rabbit proteins or to any product excipients, or who have active acute or chronic infections that contraindicate any additional immunosuppression , and dose reductions are required when the WBC count is between 2,000 and 3,000 cells/mm3 or if the platelet count is between 50,000 and 75,000 cells/mm3 . Humana requires prior authorization through its transplant network: preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300 or by phone at 866-421-5663 , and Humana MA may apply step therapy requirements for some drugs under its Part B Step Therapy Preferred Drug List. To prevent disruption of care, Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to enrollment, though Humana may review services furnished during an active course of treatment against permissible coverage criteria when determining payment .

- For kidney transplant rejection prophylaxis or treatment, the request aligns squarely with the FDA label: Thymoglobulin is indicated for the prophylaxis and treatment of acute rejection in adult and pediatric patients receiving a kidney transplant in conjunction with concomitant immunosuppression , and the drug is indicated for management of allograft rejection episodes in renal transplantation and is covered under Medicare when used for this purpose per CMS NCD 260.7 - KDIGO clinical practice guidelines support ATG-based induction in kidney transplant recipients, particularly those at high immunologic risk; anti-thymocyte globulin is a highly efficient induction agent that can prevent acute rejection and delayed graft function and is widely used for biopsy-confirmed acute rejection reversal and steroid-resistant rejection - For steroid-resistant or vascular rejection, ATG is the guideline-endorsed standard: ATG is a pivotal immunosuppressive therapy utilized in the management of T-cell-mediated rejection and steroid-resistant rejection among renal transplant recipients ; an IL-2 receptor antagonist (basiliximab) is not an appropriate substitute for treatment of established rejection, so step-therapy requirements should be waived - Dosing requested matches the FDA-approved regimen of 1.5 mg/kg of body weight administered daily for 4 to 7 days for induction, or a 7 to 14 day course of daily infusion of 1.5 mg/kg of Thymoglobulin for treatment of acute rejection, consistent with the package insert and LiverTox/NIH summaries - Thymoglobulin is preferred over equine ATG in high-risk recipients: multiple studies have indicated that thymoglobulin is favored in comparison to other induction agents for patients who have increased risk of developing post-transplant complications, such as elderly patients, patients undergoing a repeat transplantation, and patients in which minimization of use of steroids or CNIs post-operation is recommended — relevant for the Medicare Advantage population - Humana's own policy framework grants continuity-of-care protection: Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to enrollment , and members can request expedited exception reviews for step therapy prior authorization requests - Contraindication-based denials should be rebutted with documentation that the patient has no history of allergy or anaphylaxis to rabbit proteins or to any product excipients, or active acute or chronic infections that contraindicate any additional immunosuppression , satisfying the only FDA-labeled contraindications

## Why Humana Denied rATG as "Duplicate Therapy" — and How to Appeal

Rabbit anti-thymocyte globulin (rATG) is a lymphocyte-depleting immunosuppressive agent used primarily in solid organ transplantation (for induction immunosuppression or rejection treatment) and in certain hematologic conditions including aplastic anemia. A "duplicate therapy" denial from Humana means the insurer has determined that another immunosuppressive or induction agent already approved or administered is therapeutically equivalent to rATG, making a second agent redundant in their view.

This denial type is often based on an automated clinical-edit review that flags co-administration of two agents with overlapping mechanistic descriptions. However, rATG has a specific mechanism — polyclonal T-cell depletion — that is not replicated by many other immunosuppressives, and its use alongside maintenance agents (such as calcineurin inhibitors or steroids) is standard transplant protocol, not true duplication.

## Why This Denial Is Appealable

Duplicate-therapy edits are designed to prevent truly redundant prescribing, not to second-guess transplant or hematology protocols that combine agents with different mechanisms for complementary purposes. If rATG is being used for induction or rejection treatment while the patient is also on maintenance immunosuppression, these are not duplicative — they serve distinct, non-overlapping clinical roles. This distinction is documentable and is a strong basis for appeal.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your Explanation of Benefits (EOB), typically 180 days from the denial date.
• ACA §2719 / external review: After a final internal denial, you are entitled to independent external review by a certified Independent Review Organization (IRO). The standard window is approximately four months from the final internal denial. Expedited review (72-hour decision) is available for urgent clinical situations, including active rejection episodes.
• ERISA §503: If the plan is employer-sponsored, Humana must disclose every clinical standard and guideline used in the duplicate-therapy determination and must provide a full-and-fair review.

## Concrete Appeal Steps

1. Obtain the full denial letter, including the specific clinical edit or policy that triggered the duplicate-therapy flag. 2. Identify the other agent Humana considers duplicative and document the mechanistic and clinical differences between it and rATG. 3. Have the transplant physician or specialist write a medical-necessity letter explaining the distinct therapeutic roles of each agent. 4. Cite the applicable professional society protocol (e.g., from the relevant transplant or hematology society) — reference the organization, not specific numbers. 5. Submit the internal appeal before the EOB deadline with full documentation. 6. If denied, escalate to external review immediately.

## Documentation to Gather

• Diagnosis and clinical indication: Chart notes confirming the transplant or hematologic diagnosis and the clinical context in which rATG is being used (induction, rejection treatment, or other indication).
• Treatment protocol documentation: The prescribing clinician's documentation of the full immunosuppressive regimen, explaining why each agent is included and why rATG is not redundant with any other agent on the regimen.
• Prescriber medical-necessity letter: A letter from the transplant surgeon, transplant nephrologist/hepatologist, or hematologist specifically rebutting the duplicate-therapy characterization and explaining the non-overlapping role of rATG.
• Relevant guideline reference: A citation to the applicable professional society guidelines (by organization name) supporting combination therapy in this clinical scenario.

## Criteria-Mapping Structure

Obtain Humana's published coverage policy for rATG and the specific duplicate-therapy edit applied. Build a two-column table: left column lists each duplicate-therapy criterion; right column cites the chart note or clinician letter demonstrating that rATG serves a mechanistically and clinically distinct function. A clear mechanistic rebuttal — grounded in the chart, not just a generic objection — is the most effective response to this denial type.